142 related articles for article (PubMed ID: 1357518)
1. Cell cycle dependent regulation of IMP dehydrogenase activity and effect of tiazofurin.
Szekeres T; Fritzer M; Pillwein K; Felzmann T; Chiba P
Life Sci; 1992; 51(16):1309-15. PubMed ID: 1357518
[TBL] [Abstract][Full Text] [Related]
2. Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient.
Weber G; Nagai M; Natsumeda Y; Eble JN; Jayaram HN; Paulik E; Zhen WN; Hoffman R; Tricot G
Cancer Commun; 1991 Mar; 3(3):61-6. PubMed ID: 1705812
[TBL] [Abstract][Full Text] [Related]
3. Tiazofurin: molecular and clinical action.
Weber G; Prajda N; Abonyi M; Look KY; Tricot G
Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
[TBL] [Abstract][Full Text] [Related]
4. GM-CSF: modulation of biochemical and cytotoxic effects of tiazofurin in HL-60 cells.
Fritzer M; Gharehbaghi K; Pillwein K; Chiba P; Goldenberg H; Szekeres T
Br J Haematol; 1993 Jul; 84(3):552-4. PubMed ID: 8105873
[TBL] [Abstract][Full Text] [Related]
5. Tiazofurin decreases Ras-GTP complex in K562 cells.
Hata Y; Natsumeda Y; Weber G
Oncol Res; 1993; 5(4-5):161-4. PubMed ID: 8305741
[TBL] [Abstract][Full Text] [Related]
6. Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot GJ; Jayaram HN; Lapis E; Natsumeda Y; Nichols CR; Kneebone P; Heerema N; Weber G; Hoffman R
Cancer Res; 1989 Jul; 49(13):3696-701. PubMed ID: 2567208
[TBL] [Abstract][Full Text] [Related]
7. Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
Prajda N; Hata Y; Abonyi M; Singhal RL; Weber G
Cancer Res; 1993 Dec; 53(24):5982-6. PubMed ID: 7903199
[TBL] [Abstract][Full Text] [Related]
8. Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas.
Look KY; Sutton GP; Natsumeda Y; Eble JN; Stehman FB; Ehrlich CE; Olah E; Prajda N; Bosze P; Eckhardt S
Gynecol Oncol; 1992 Oct; 47(1):66-70. PubMed ID: 1358769
[TBL] [Abstract][Full Text] [Related]
9. Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
Weber G; Jayaram HN; Lapis E; Natsumeda Y; Yamada Y; Yamaji Y; Tricot GJ; Hoffman R
Adv Enzyme Regul; 1988; 27():405-33. PubMed ID: 2907968
[TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin.
Weber G; Yamaji Y; Olah E; Natsumeda Y; Jayaram HN; Lapis E; Zhen WN; Prajda N; Hoffman R; Tricot GJ
Adv Enzyme Regul; 1989; 28():335-56. PubMed ID: 2576178
[TBL] [Abstract][Full Text] [Related]
11. Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.
Tricot G; Weber G
Anticancer Res; 1996; 16(6A):3341-7. PubMed ID: 9042309
[TBL] [Abstract][Full Text] [Related]
12. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Wright DG; Boosalis M; Malek K; Waraska K
Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
[TBL] [Abstract][Full Text] [Related]
13. Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells.
Olah E; Natsumeda Y; Ikegami T; Kote Z; Horanyi M; Szelenyi J; Paulik E; Kremmer T; Hollan SR; Sugar J
Proc Natl Acad Sci U S A; 1988 Sep; 85(17):6533-7. PubMed ID: 2901100
[TBL] [Abstract][Full Text] [Related]
14. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture.
Lee HJ; Pawlak K; Nguyen BT; Robins RK; Sadée W
Cancer Res; 1985 Nov; 45(11 Pt 1):5512-20. PubMed ID: 2865005
[TBL] [Abstract][Full Text] [Related]
15. IMP dehydrogenase: inhibition by the anti-leukemic drug, tiazofurin.
Yamada Y; Natsumeda Y; Yamaji Y; Jayaram HN; Tricot GJ; Hoffman R; Weber G
Leuk Res; 1989; 13(2):179-84. PubMed ID: 2564451
[TBL] [Abstract][Full Text] [Related]
16. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
Lui MS; Faderan MA; Liepnieks JJ; Natsumeda Y; Olah E; Jayaram HN; Weber G
J Biol Chem; 1984 Apr; 259(8):5078-82. PubMed ID: 6143752
[TBL] [Abstract][Full Text] [Related]
17. Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5'-phosphate dehydrogenase.
Sokoloski JA; Blair OC; Sartorelli AC
Cancer Res; 1986 May; 46(5):2314-9. PubMed ID: 2870796
[TBL] [Abstract][Full Text] [Related]
18. Induction of the differentiation of synchronized HL-60 leukemia cells by tiazofurin.
Sokoloski JA; Blair OC; Carbone R; Sartorelli AC
Exp Cell Res; 1989 May; 182(1):234-41. PubMed ID: 2714402
[TBL] [Abstract][Full Text] [Related]
19. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.
Jayaram HN; Cooney DA; Grusch M; Krupitza G
Curr Med Chem; 1999 Jul; 6(7):561-74. PubMed ID: 10390601
[TBL] [Abstract][Full Text] [Related]
20. IMP dehydrogenase inhibitor, tiazofurin, induces apoptosis in K562 human erythroleukemia cells.
Vitale M; Zamai L; Falcieri E; Zauli G; Gobbi P; Santi S; Cinti C; Weber G
Cytometry; 1997 Feb; 30(1):61-6. PubMed ID: 9056744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
